LYT-200 is under clinical development by Puretech Health and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I drugs for Myelodysplastic Syndrome have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LYT-200’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LYT-200 overview

LYT-200 is under development for the treatment of solid tumors such as liver cancer, metastatic pancreatic cancer, metastatic cholangiocarcinoma, autoimmune disorders, melanoma, metastatic transitional (urothelial) tract cancer, ureter cancer, bladder cancer, head and neck cancer squamous cell carcinoma, oral cavity (mouth) cancer, oropharyngeal cancer, hypopharyngeal cancer, acute myelocytic leukemia, relapsed or refractory acute myeloid leukemia and refractory acute myeloid leukemia myelodysplastic syndrome, B-Cell Acute Lymphocytic Leukemia (B-ALL), T-ALL, diffuse large B-Cell lymphoma (DLBCL), pancreatic ductal adenocarcinoma and metastatic colorectal cancer. The drug candidate acts by targeting galectin-9. It is administered through intravenous route.

Puretech Health overview

Puretech Health (Puretech), a subsidiary of Royalty Pharma Plc, is a biotherapeutics company that discovers, develops, and commercializes drugs to treat lung dysfunction, immuno-oncology, lymphatic, neurological and neuropsychological disorders. The company is pipeline products include LYT-100 (deupirfenidone), targeting inflammation and fibrosis, lymphedema, and SARS-CoV-2 respiratory problems; LYT-200, a human monoclonal antibody for the treatment of pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC) and cholangiocarcinoma (CCA); and LYT-210, a gamma delta-1 T cell receptor against solid tumors. It is also evaluating LYT-300, oral allopregnanolone for neurological indications. Puretech works in collaboration with pharmaceutical and biotechnology companies to develop its products. Puretech is headquartered in Boston, Massachusetts, the US.

For a complete picture of LYT-200’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.